SCHEMBL11944245

SCHEMBL11944245

O=c1c(OC2CCCC2)c(N2CCN(S(=O)(=O)Cc3ccccc3)CC2)cnn1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HSD11B1 P28845 1/20 0.40
▸ NPBWR1 P48145 1/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ DCTPP1 Q9H773 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ MCOLN2 Q8IZK6 1/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.38
▸ MCOLN1 Q9GZU1 1/20 0.38
▸ SMO Q99835 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944645 0.93 MAPT (0.40) MAPTLMNAKMT2ANPBWR1MCHR1
SCHEMBL11944647 0.92 HTR1A (0.41) MAPTLMNAKMT2ANPBWR1MCHR1
SCHEMBL11944285 0.92 CYP3A4 (0.45) MAPTLMNAKMT2ANPBWR1MCHR1
SCHEMBL11944650 0.90 ENPP2 (0.38) MAPTLMNANPBWR1MCHR1ALDH1A1
SCHEMBL11945125 0.90 MAPT (0.46) MAPTLMNAALDH1A1TP53DCTPP1
SCHEMBL11944648 0.90 MET (0.41) MAPTLMNANPBWR1MCHR1ALDH1A1
SCHEMBL11944021 0.90 MAPT (0.46) MAPTALDH1A1TP53DCTPP1POLB
SCHEMBL11945231 0.89 MAPT (0.54) MAPTLMNAKMT2AALDH1A1TP53
SCHEMBL11944194 0.89 POLB (0.46) MAPTNPBWR1MCHR1ALDH1A1TP53
SCHEMBL11943960 0.89 MAPT (0.51) MAPTALDH1A1TP53DCTPP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885LMNA 929/4885KMT2A 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback